- Home
- CISS vs SCNI Comparison
CISS vs SCNI Comparison
Compare CISS & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- SCNI
- Stock Information
- Founded
- CISS 2022
- SCNI 2003
- Country
- CISS Greece
- SCNI Israel
- Employees
- CISS N/A
- SCNI N/A
- Industry
- CISS Marine Transportation
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CISS Consumer Discretionary
- SCNI Health Care
- Exchange
- CISS Nasdaq
- SCNI Nasdaq
- Market Cap
- CISS 3.1M
- SCNI 1.9M
- IPO Year
- CISS N/A
- SCNI N/A
- Fundamental
- Price
- CISS $3.85
- SCNI $2.80
- Analyst Decision
- CISS
- SCNI
- Analyst Count
- CISS 0
- SCNI 0
- Target Price
- CISS N/A
- SCNI N/A
- AVG Volume (30 Days)
- CISS 30.6K
- SCNI 22.4K
- Earning Date
- CISS 05-27-2025
- SCNI 07-01-2025
- Dividend Yield
- CISS N/A
- SCNI N/A
- EPS Growth
- CISS N/A
- SCNI N/A
- EPS
- CISS N/A
- SCNI 5.95
- Revenue
- CISS $42,296,101.00
- SCNI $658,000.00
- Revenue This Year
- CISS N/A
- SCNI N/A
- Revenue Next Year
- CISS N/A
- SCNI N/A
- P/E Ratio
- CISS N/A
- SCNI $0.47
- Revenue Growth
- CISS 47.17
- SCNI N/A
- 52 Week Low
- CISS $2.85
- SCNI $1.90
- 52 Week High
- CISS $29.40
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- CISS 48.93
- SCNI 57.37
- Support Level
- CISS $3.75
- SCNI $2.64
- Resistance Level
- CISS $4.10
- SCNI $2.69
- Average True Range (ATR)
- CISS 0.29
- SCNI 0.21
- MACD
- CISS 0.08
- SCNI 0.09
- Stochastic Oscillator
- CISS 67.78
- SCNI 84.27
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.